Pradip De
Impact in
- Cancer Research top 5%
- Cancer Genomics and Diagnostics
- Oncology top 2%
- HER2/EGFR in Cancer Research
- Cancer Cells and Metastasis
- Cancer-related Molecular Pathways
- Cancer Immunotherapy and Biomarkers
Papers in
- Oncology 20
- HER2/EGFR in Cancer Research 7
- Cancer-related Molecular Pathways 6
- Cancer Cells and Metastasis 5
-
- PI3K/AKT/mTOR signaling in cancer 7
- Wnt/β-catenin signaling in development and cancer 3
- Co-authors
- Nandini Dey (28 shared papers)Brian Leyland‐Jones (18 shared papers)Casey Williams (8 shared papers)Jennifer C. Aske (8 shared papers)Jennifer Carlson (6 shared papers)Razelle Kurzrock (7 shared papers)Shumei Kato (7 shared papers)Scott M. Lippman (4 shared papers)
- Journals
- International Journal of Molecular Sciences (3 papers)Cancers (3 papers)Journal of Clinical Oncology (2 papers)Oncotarget (2 papers)Cancer Treatment Reviews (2 papers)
- Partner nations
- United StatesCanadaNetherlands
In The Last Decade
Pradip De
36 papers receiving 2.0k citations
Pradip De's Hit Papers
Peers
Comparison fields: 5 of 87
- Cancer Research 502
- Oncology 874
- Molecular Biology 917
- Pulmonary and Respiratory Medicine 369
- Pathology and Forensic Medicine 163
Countries citing papers authored by Pradip De
This map shows the geographic impact of Pradip De's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Pradip De with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Pradip De more than expected).
Fields of papers citing papers by Pradip De
This network shows the impact of papers produced by Pradip De. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Pradip De. The network helps show where Pradip De may publish in the future.
Co-authors
The 25 scholars most cited alongside Pradip De, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 36 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | Molecular profiling of cancer patients enables personalized combination therapy: the I-PREDICT study Hit paper breakdown → | 2019 | 442 |
| 2 | 2013 | 218 | |
| 3 | 2017 | 185 | |
| 4 | The trastuzumab era: current and upcoming targeted HER2+ breast cancer therapies. | 2020 | 129 |
| 5 | 2017 | 93 | |
| 6 | 2014 | 89 | |
| 7 | 2019 | 80 | |
| 8 | 2021 | 65 | |
| 9 | 2002 | 64 | |
| 10 | 2014 | 64 | |
| 11 | 2013 | 63 | |
| 12 | ER+ metastatic breast cancer: past, present, and a prescription for an apoptosis-targeted future. | 2019 | 58 |
| 13 | 2016 | 57 | |
| 14 | A critical role for HER3 in HER2-amplified and non-amplified breast cancers: function of a kinase-dead RTK. | 2015 | 51 |
| 15 | MYC-xing it up with PIK3CA mutation and resistance to PI3K inhibitors: summit of two giants in breast cancers. | 2015 | 41 |
| 16 | 2021 | 36 | |
| 17 | A combination of the PI3K pathway inhibitor plus cell cycle pathway inhibitor to combat endocrine resistance in hormone receptor-positive breast cancer: a genomic algorithm-based treatment approach. | 2018 | 34 |
| 18 | 2017 | 33 | |
| 19 | 2013 | 28 | |
| 20 | Anti-tumor efficacy of BEZ235 is complemented by its anti-angiogenic effects via downregulation of PI3K-mTOR-HIF1alpha signaling in HER2-defined breast cancers. | 2016 | 28 |
About Pradip De
Pradip De is a scholar working on Oncology, Molecular Biology, Cancer Research, Pulmonary and Respiratory Medicine and Radiology, Nuclear Medicine and Imaging, having authored 36 papers that have together received 2.0k indexed citations. Recurring topics across this work include Cancer Genomics and Diagnostics (7 papers), HER2/EGFR in Cancer Research (7 papers), PI3K/AKT/mTOR signaling in cancer (7 papers), Advanced Breast Cancer Therapies (6 papers), Cancer-related Molecular Pathways (6 papers), Cancer Cells and Metastasis (5 papers), Wnt/β-catenin signaling in development and cancer (3 papers) and Monoclonal and Polyclonal Antibodies Research (3 papers). The work is most often cited by research in Cancer Research (502 citations), Oncology (874 citations), Molecular Biology (917 citations), Pulmonary and Respiratory Medicine (369 citations) and Pathology and Forensic Medicine (163 citations). Pradip De has collaborated with scholars based in United States, Canada and Netherlands. Frequent co-authors include Nandini Dey, Brian Leyland‐Jones, Casey Williams, Jennifer C. Aske, Jennifer Carlson, Razelle Kurzrock, Shumei Kato, Scott M. Lippman, Michael E. Hahn and Paul T. Fanta. Their work appears in journals such as International Journal of Molecular Sciences, Cancers, Journal of Clinical Oncology, Oncotarget and Cancer Treatment Reviews.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.